Stockhub

Soligenix, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

14 August 2022

10 August 2022

  • curprev 07:0307:03, 10 August 2022 109.180.50.163 talk 1,616 bytes +1,616 Created page with "Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator..."
Retrieved from "https://stockhub.co/research/Soligenix,_Inc."